You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 83 No. 6, JUNE 1949 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

CLINICAL STUDIES ON DICUMAROL® HYPOPROTHROMBINEMIA AND VITAMIN K PREPARATIONS

I. Superiority of Vitamin K1 Oxide Over Menadione Sodium Bisulfite U.S.P. and Synkayvite® in Reversing Dicumarol Hypoprothrombinemia

DAVID F. JAMES, M.D.; IVAN L. BENNETT, Jr., M.D.; PERITZ SCHEINBERG, M.D.; JOHN J. BUTLER, M.D.

Arch Intern Med. 1949;83(6):632-652.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE HYPOPROTHROMBINEMIA induced with dicumarol® (3, 3,3'-methylene-bis-[4-hydroxycoumarin] ) is much more difficult to control than that which is the result of obstructive jaundice and other states characterized by deficient intake or absorption of vitamin K. Substances which have vitamin K activity in amount sufficient to reverse the hypoprothrombinemia of the latter states are wholly inadequate against the effect of dicumarol.® This report describes observations on the effect of three different compounds with vitamin K activity on the hypoprothrombinemia of human beings after dicumarol® therapy. Determination of the rapidity and degree to which the hypoprothrombinemia induced with this agent can be reversed is a logical and safe method of investigating the efficacy of these agents in man and is the basis on which these studies have been made.

There is general agreement that when bleeding occurs as the result of dicumarol® poisoning the main cause is prothrombin deficiency. . . . [Full Text PDF of this Article]


Author Affiliations

ATLANTA, GA.

From the Department of Medicine, Emory University School of Medicine, and the Medical Service, Grady Hospital.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1949 American Medical Association. All Rights Reserved.